Will DigitalOcean Stock Bounce Back?
DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…
Sell
42
CRL Quote, Financials, Valuation and Earnings
Last price:
$136.75
Seasonality move
:
5.27%
Day range:
$133.34 - $136.26
52-week range:
$91.86 - $254.15
Dividend yield:
0%
P/E ratio:
913.13x
P/S ratio:
1.73x
P/B ratio:
2.09x
Volume:
1.3M
Avg. volume:
2.2M
1-year change:
-38.08%
Market cap:
$6.7B
Revenue:
$4B
EPS (TTM):
-$0.65
Analysts' Opinion
-
Consensus RatingCharles River Laboratories International has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 15 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $159.28, Charles River Laboratories International has an estimated upside of 17.46% from its current price of $135.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $70.00 representing 100% downside risk from its current price of $135.60.
Fair Value
-
According to the consensus of 19 analysts, Charles River Laboratories International has 17.46% upside to fair value with a price target of $159.28 per share.
CRL vs. S&P 500
-
Over the past 5 trading days, Charles River Laboratories International has underperformed the S&P 500 by -0.42% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Charles River Laboratories International does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Charles River Laboratories International revenues have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Charles River Laboratories International reported revenues of $984.2M.
Earnings Growth
-
Charles River Laboratories International earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Charles River Laboratories International reported earnings per share of $0.50.
Enterprise value:
9B
EV / Invested capital:
1.56x
Price / LTM sales:
1.73x
EV / EBIT:
60.23x
EV / Revenue:
2.23x
PEG ratio (5yr expected):
--
EV / Free cash flow:
15.96x
Price / Operating cash flow:
12.38x
Enterprise value / EBITDA:
16.46x
Gross Profit (TTM):
$1.3B
Return On Assets:
-0.4%
Net Income Margin (TTM):
-0.79%
Return On Equity:
-0.87%
Return On Invested Capital:
-0.52%
Operating Margin:
7.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $4.1B | $4.1B | $4B | $1B | $984.2M | |
| Gross Profit | $1.5B | $1.5B | $1.3B | $344.8M | $317.7M | |
| Operating Income | $670.1M | $575.3M | $391M | $126M | $74.7M | |
| EBITDA | $1B | $1B | $546M | $219.4M | $184.2M | |
| Diluted EPS | $9.67 | $8.52 | -$0.65 | $1.30 | $0.50 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.4B | $1.3B | $1.4B | $1.7B | $1.5B | |
| Total Assets | $5.8B | $7.1B | $7.7B | $8.2B | $7.6B | |
| Current Liabilities | $803.4M | $993.8M | $981.4M | $954.8M | $1.1B | |
| Total Liabilities | $3.6B | $4.4B | $4.5B | $4.4B | $4.3B | |
| Total Equity | $2.2B | $2.7B | $3.2B | $3.7B | $3.2B | |
| Total Debt | $2.2B | $2.7B | $2.7B | $2.7B | $2.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $626.4M | $704.4M | $776.4M | $129.9M | $171.7M | |
| Cash From Investing | -$678.5M | -$480.3M | -$204.8M | -$85.8M | -$45.5M | |
| Cash From Financing | -$3.9M | -$92.4M | -$674.6M | $18.3M | -$105.3M | |
| Free Cash Flow | $275.2M | $413.6M | $563.2M | $50.7M | $112.4M | |
CRL
Sector
Market Cap
$6.7B
$34.8M
Price % of 52-Week High
53.35%
44.26%
Dividend Yield
0%
0%
Shareholder Yield
6.63%
-0.59%
1-Year Price Total Return
-38.08%
-42.23%
Beta (5-Year)
1.500
0.659
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$139.79
200-day SMA
Sell
Level
$174.95
Bollinger Bands (100)
Sell
Level
128.4 - 177.24
Chaikin Money Flow
Buy
Level
9.6M
20-day SMA
Buy
Level
$130.72
Relative Strength Index (RSI14)
Buy
Level
52.53
ADX Line
Buy
Level
31.85
Williams %R
Neutral
Level
-35.6688
50-day SMA
Sell
Level
$135.77
MACD (12, 26)
Buy
Level
8.32
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Sell
Level
-10.4M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.4453)
Sell
CA Score
(Annual)
Level (-0.3719)
Buy
Beneish M-Score
(Annual)
Level (-2.9543)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (23.3062)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Stock Forecast FAQ
In the current month, CRL has received 3 Buy ratings 15 Hold ratings, and 1 Sell ratings. The CRL average analyst price target in the past 3 months is $159.28.
-
Where Will Charles River Laboratories International Stock Be In 1 Year?
According to analysts, the consensus estimate is that Charles River Laboratories International share price will rise to $159.28 per share over the next 12 months.
-
What Do Analysts Say About Charles River Laboratories International?
Analysts are divided on their view about Charles River Laboratories International share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Charles River Laboratories International is a Sell and believe this share price will drop from its current level to $70.00.
-
What Is Charles River Laboratories International's Price Target?
The price target for Charles River Laboratories International over the next 1-year time period is forecast to be $159.28 according to 19 Wall Street analysts, 3 of them rate the stock a Buy, 1 rates the stock a Sell, and 15 analysts rate the stock a Hold.
-
Is CRL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Charles River Laboratories International is a Hold. 15 of 19 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CRL?
You can purchase shares of Charles River Laboratories International via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Charles River Laboratories International shares.
-
What Is The Charles River Laboratories International Share Price Today?
Charles River Laboratories International was last trading at $136.75 per share. This represents the most recent stock quote for Charles River Laboratories International. Yesterday, Charles River Laboratories International closed at $135.60 per share.
-
How To Buy Charles River Laboratories International Stock Online?
In order to purchase Charles River Laboratories International stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Cognizant Stock Be In 5 Years?
Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…
NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
66
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
54
AAP alert for May 23
Advance Auto Parts [AAP] is down 0.98% over the past day.
Buy
67
IONQ alert for May 23
IonQ [IONQ] is down 0.48% over the past day.
Buy
75
URBN alert for May 23
Urban Outfitters [URBN] is down 1.24% over the past day.
